ClinicalTrials.gg
CompletedNCT07121959Updated Oct 15, 2025

A Study of Belzutifan (MK-6482) and Metformin in Healthy Adult Participants (MK-6482-039)

A Phase 1 interventional study of Metformin and Belzutifan in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The goal of this study is to learn how belzutifan (MK-6482) affects the levels of metformin in a healthy person's body over time. Researchers will study levels of metformin in the blood and urine in healthy volunteers after taking metformin alone (Period 1) and metformin with belzutifan (Period 2).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

The main inclusion criteria include, but are not limited to:

  • Is a continuous non-smoker for at least 3 months prior to dosing
  • Has (BMI) ≥ 18.0 and ≤ 42.0 kg/m2
  • Is able to swallow multiple tablets

The main exclusion criteria include, but are not limited to:

  • Has a history of cancer ()
  • Has a history of anemia within the last 5 years
  • Has a known history or presence of metabolic acidosis, ketoacidosis, or lactic acidosis
  • Has a level below the lower limit of normal
  • Has a pulse oximetry reading less than 92% at rest
  • Is known to be a cytochrome P450 (CYP2C19) poor metabolizer or likely poor metabolizer based on genotyping prior to the screening visit or is determined to be a CYP2C19 poor metabolizer
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Metformin

    On Day 1 of Period 1, a single dose of metformin will be administered.

    Drug: Metformin

  • Experimental
    Belzutifan with Metformin

    In Period 2, belzutifan will be administered every day for 5 consecutive days with a single dose of metformin coadministered on Day 4.

    Drug: Metformin · Drug: Belzutifan

Interventions

  • Oral Tablet

    Also known as: Metformin HCl

  • Oral Tablet

    Also known as: MK-6482

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) for Metformin in Plasma

    Blood samples will be collected to determine the AUC0-inf of metformin in plasma.

    Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)

Secondary outcomes

  1. Number of Participants Who Experience One or More Adverse Events (AEs)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: Up to approximately 4 weeks

  2. Number of Participants Who Discontinue Study Drug Due to an AE

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: Up to approximately 2 weeks

  3. Area Under the Concentration Versus Time Curve from 0 to the Last Quantifiable Sample (AUC0-last) of Metformin

    Plasma samples will be collected to determine the AUC0-last of metformin.

    Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)

  4. Area Under the Concentration Versus Time Curve from 0 to 24 hours (AUC0-24) of Metformin

    Plasma samples will be collected to determine the AUC0-24 of metformin.

    Time frame: At designated timepoints (up to approximately 24 hours post-dose metformin)

  5. Maximum Observed Concentration (Cmax) of Metformin

    Plasma samples will be collected to determine the Cmax of metformin.

    Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)

  6. Plasma Drug Concentration of Metformin at Hour 24 (C24)

    Plasma samples will be collected to determine the C24 of metformin.

    Time frame: 24 hours post-dose metformin

  7. Time to Maximum Concentration (Tmax) of Metformin

    Plasma samples will be collected to determine the Tmax of metformin.

    Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)

  8. Apparent Terminal Half-life (t1/2) of Metformin

    Plasma samples will be collected to determine the t1/2 of metformin.

    Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)

  9. Apparent Clearance (CL/F) of Metformin

    Plasma samples will be collected to determine the CL/F of metformin.

    Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)

  10. Apparent Volume of Distribution During Terminal Phase (Vz/F) of Metformin

    Plasma samples will be collected to determine the Vz/F of metformin.

    Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)

  11. Total Amount of Metformin Excreted Unchanged in the Urine

    Urine samples will be collected to determine the total amount of metformin excreted unchanged in the urine.

    Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)

  12. Percentage of Metformin Excreted Unchanged in Urine

    Urine samples will be collected to determine the percentage of metformin excreted unchanged in urine.

    Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)

  13. Renal Clearance of Metformin

    Urine samples will be collected to determine the renal clearance of metformin.

    Time frame: At designated timepoints (up to approximately 48 hours post-dose metformin)

07

Study locations

1 site
  • Celerion ( Site 0001)
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Sep 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Aug 14, 2025
StartActual
Aug 18, 2025
Primary completionActual
Sep 13, 2025
CompletionActual
Sep 26, 2025
Last update
Oct 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07121959
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Aug 18, 2025
Primary completion
Sep 13, 2025
Completion
Sep 26, 2025
Last update
Oct 15, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Belzutifan

Start the discussion